IMMUNOGLOBULIN FC POLYPEPTIDES
First Claim
1. A polypeptide comprising an aglycosylated antibody Fc domain capable of binding a human FcR polypeptide, wherein the Fc domain comprises an amino acid substitution at amino acids 382 and 428 and at least one additional substitution of any of the following amino acids:
- 224, 241, 251, 266, 269, 276, 279, 286, 295, 297, 300, 315, 325, 328, 330, 331, 332, 338, 340, 341, 348, 369, 378, 382, 392, 424, 426, 428 and/or 434.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fe domain that selectively binds FcγRI at a level within 2-fold of a glycosylated Fc domain, but that is significantly reduced for binding to other Fc receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain.
-
Citations
116 Claims
-
1. A polypeptide comprising an aglycosylated antibody Fc domain capable of binding a human FcR polypeptide, wherein the Fc domain comprises an amino acid substitution at amino acids 382 and 428 and at least one additional substitution of any of the following amino acids:
- 224, 241, 251, 266, 269, 276, 279, 286, 295, 297, 300, 315, 325, 328, 330, 331, 332, 338, 340, 341, 348, 369, 378, 382, 392, 424, 426, 428 and/or 434.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 36)
-
34. (canceled)
-
35. (canceled)
-
37-41. -41. (canceled)
-
42. A polypeptide comprising an aglycosylated Fc domain capable of binding an FcRγ
- I polypeptide and a second binding domain, wherein the second binding domain is capable of binding a cell-surface molecule.
-
43-54. -54. (canceled)
-
55. A method for preparing an aglycosylated polypeptide comprising:
-
a) obtaining a host cell capable of expressing an aglycosylated antibody comprising an Fc domain capable of binding an FcR polypeptide, wherein the Fc domain comprises an amino acid substitution at amino acids 382 and 428 and at least one additional substitution of any of the following amino acids;
224, 241, 251, 266, 269, 276, 279, 286, 295, 297, 300, 315, 325, 328, 330, 331, 332, 338, 340, 341, 348, 369, 378, 382, 392, 424, 426, 428 and/or 434;b) incubating the host cell in culture under conditions to promote expression of the aglycosylated antibody; and
,c) purifying expressed antibody from the host cell.
-
-
56-60. -60. (canceled)
-
61. A method of inducing an immune response in a subject with an antibody comprising providing to the subject with the antibody, wherein the antibody is aglycosylated and comprises an Fc domain capable of binding an Fcγ
- RI polypeptide, wherein the Fc domain comprises an amino acid substitution at amino acids 382 and 428 and at least one additional substitution of any of the following amino acids;
224, 241, 251, 266, 269, 276, 279, 286, 295, 297, 300, 315, 325, 328, 330, 331, 332, 338, 340, 341, 348, 369, 378, 382, 392, 424, 426, 428 and/or 434.
- RI polypeptide, wherein the Fc domain comprises an amino acid substitution at amino acids 382 and 428 and at least one additional substitution of any of the following amino acids;
-
62-64. -64. (canceled)
-
65. A method of inducing dendritic cell—
- (DC) mediated cell killing against a target cell expressing a targeted cell surface polypeptide comprising;
a) contacting the target cell with a polypeptide comprising a mutated and aglycosylated Fc domain capable of specifically binding at least an Fcγ
RI polypeptide and second binding domain that binds the targeted cell surface polypeptide, wherein the aglycosylated Fc domain specifically binds to an Fcγ
RIIB polypeptide at a level that is at least 50-fold less than a glycosylated Fc domain; andb) exposing the target cell to dendritic cells under conditions that promote killing of the target cell.
- (DC) mediated cell killing against a target cell expressing a targeted cell surface polypeptide comprising;
-
66. (canceled)
-
67. (canceled)
-
68. A method for screening for an aglycosylated polypeptide having an Fc domain that binds a specific Fcγ
- R polypeptides comprising;
a) obtaining a population of Gram negative bacterial cells, cells of which population express a aglycosylated polypeptide comprising an Fc domain in their periplasm, wherein the population expresses a plurality of different Fc domains; b) contacting the bacterial cells with a first FcR polypeptide under conditions to allow contact between the Fcγ
R polypeptide and the aglycosylated Fc domains, wherein the Fcγ
R polypeptide is Fcγ
RIa, Fcγ
RIIa, Fcγ
RIIb, Fcγ
RIIc, Fcγ
RIIIa, Fcγ
RIIIb, or Fcα
RI;c) selecting at least one bacterial cell based on binding of the aglycosylated Fc domain to the first FcR polypeptide.
- R polypeptides comprising;
-
69-115. -115. (canceled)
-
116. A method for optimizing Fc binding to one or more specific FcR polypeptides of an aglycosylated polypeptide having an Fc domain comprising:
-
a) obtaining a population of Gram negative bacterial cells, cells of which population express a aglycosylated polypeptide comprising an Fc domain in their periplasm, wherein the population expresses a plurality of different polypeptides expressing different mutated Fc domains; b) contacting the bacterial cells with a first FcR polypeptide under conditions to allow contact between the FcR polypeptide and the aglycosylated Fc domains, wherein the FcR polypeptide is Fcγ
RIa, Fcγ
RIIa, Fcγ
RIIb, Fcγ
RIIc, Fcγ
RIIIa, Fcγ
RIIIb, or Fcα
RI;c) selecting at least one bacterial cell based on binding of the aglycosylated Fc domain to the first FcR polypeptide.
-
Specification